Main description:

Drawing on years of significant advances and developments, the editors of this third edition have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, pharmacogenomics, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules.

Contents:

Selecting the Right Targets for Cancer Therapy.- Clinical Importance of Prognostic Factors.- Genetic Markers in Sporadic Tumors.- Genetic Markers in Breast Tumors with Hereditary Predisposition.- Circulating Tumor Markers.- Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways.- Gene Expression Arrays for Pathway Analysis in Cancer Research.- Signaling Pathways in Cancer.- Estrogen Receptor Pathways and Breast Cancer.- Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics.- Angiogenesis Switch Pathways.- Apoptosis Pathways and New Anticancer Agents.- Genomic Instability, DNA Repair Pathways and Cancer.- Epigenomics and Cancer.- Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?.- Aurora Kinases: A New Target for Anticancer Drug Development.- Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways.- Suicide Gene Therapy.- Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs.- A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?.